	US 11,986,535 B2
	Method of producing an immunoligand/payload conjugate
Ulf Grawunder, Basel (CH); and Roger Renzo Beerli, Basel (CH)
Assigned to NBE THERAPEUTICS AG, Basel (CH)
Filed by NBE Therapeutics AG, Basel (CH)
Filed on Jun. 13, 2022, as Appl. No. 17/839,395.
Application 15/819,116 is a division of application No. 14/775,374, granted, now 9,872,923, issued on Jan. 23, 2018, previously published as PCT/EP2014/055173, filed on Mar. 14, 2014.
Application 17/839,395 is a continuation of application No. 16/915,343, filed on Jun. 29, 2020, granted, now 11,364,301.
Application 16/915,343 is a continuation of application No. 15/819,116, filed on Nov. 21, 2017, granted, now 10,864,277, issued on Dec. 15, 2020.
Claims priority of provisional application 61/939,754, filed on Feb. 14, 2014.
Claims priority of provisional application 61/787,371, filed on Mar. 15, 2013.
Claims priority of application No. 13159484 (EP), filed on Mar. 15, 2013.
Prior Publication US 2022/0378927 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); C07K 1/107 (2006.01); C07K 16/40 (2006.01); C12P 21/00 (2006.01)

CPC A61K 47/65 (2017.08) [A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); C07K 1/1075 (2013.01); C07K 16/40 (2013.01); C12P 21/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C12Q 2521/537 (2013.01)]

23 Claims

1. An immunoligand/payload conjugate comprising

a) an immunoligand selected from the group consisting of one or more of:

i) an antibody,

ii) an antibody-based binding protein being a protein containing at least one antibody-derived V_H, V_L, or C_Himmunoglobulin domain,

iii) an antibody fragment binding to a receptor, antigen, growth factor, cytokine, or hormone, or

iv) an antibody mimetic selected from the group consisting of DARPins, C-type lectins, A-domain proteins of S. aureus, transferrins, lipocalins, 10^thtype Ill domains of fibronectin, Kunitz domain protease inhibitors, affilins, gamma crystallin derived binders, cysteine knots or knottins, thioredoxin A scaffold based binders, nucleic acid aptamers, artificial antibodies produced by molecular imprinting of polymers, and stradobodies,

b) at least one payload having a molecular weight not exceeding 2,500 Dalton, and

c) a linker conjugating the immunoligand of (a) or a subunit thereof to the payload, said linker comprising a sortase recognition motif having its C-terminal amino acid replaced with a Gly_n, wherein n>1.